Wyeth reports additional subpoenas in Protonix probe
This article was originally published in Scrip
Wyethhas received additional subpoenas for documents from a US grand jury in Massachusetts investigating promotional practices and the pricing of its proton pump inhibitor Protonix (pantoprazole), the company said in an SEC filing. The full nature of the investigation by the US Attorney's Office for the District of Massachusetts remains unknown. Wyeth said that several current and former employees had testified before the grand jury this year. The company has been hit by launches of generic versions of Protonix in the US, which it is opposing. Last December, Teva Pharmaceutical Industrieslaunched its version "at risk" and this was followed by a launch bySun Pharmaceutical Industries; Wyeth's own generic has not offset the harm. In the SEC filing, Wyeth noted that it continues a patent infringement battle, and that a trial will begin no earlier than the fourth quarter of 2009.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.